Cáncer de páncreas exocrino

Bermejo, 2012, Epidemiología, historia natural y estadificación del cáncer de páncreas, Rev Cancer (Madrid), 26, 53 Lowenfels, 2006, Epidemiology and risk factors for pancreatic cáncer, Best Pract Res Clin Gastroenterol, 20, 197, 10.1016/j.bpg.2005.10.001 Lynch, 2002, Hereditary factors in pancreatic cancer, J Hepatobiliary Pancreat Surg, 9, 12, 10.1007/s005340200001 Tersmette, 2001, Increased rislk of incident pancreatic cancer among first-degree relatives of patients with familiar pancreatic cancer, Clin Cancer Res, 7, 738 Ben, 2011, Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies, Eur J Cancer, 47, 1928, 10.1016/j.ejca.2011.03.003 Bracci, 2009, Pancreatitis and pancreatic cancer in two large pooled case-control studies, Cancer Causes Control, 20, 1723, 10.1007/s10552-009-9424-x Fuchs, 1996, A prospective study of cigarette smoking and the risk of pancreatic cancer, Arch Intern Med, 156, 2255, 10.1001/archinte.1996.00440180119015 Jiao, 2010, Body mass index, effect modifiers and risk of pancreatic cancer: a pooled study of seven prospective cohorts, Cancer Causes Control, 21, 1305, 10.1007/s10552-010-9558-x Ojajarvi, 2000, Occupational exposures and pancreatic cancer: a meta-analysis, Occup Environ Med, 57, 316, 10.1136/oem.57.5.316 Karlson, 1999, Abdominal US for diagnosis of pancreatic tumor: prospective cohort analysis, Radiology, 213, 107, 10.1148/radiology.213.1.r99oc25107 AJCC (American Join Committee on Cancer) Cancer staging manual. 7thed. Edge SB, Byrd DR, Compton CC, Fritz AG, Green FL, Trotti A, editors. New York; Springer; 2010. p. 241. Rafael, 2012, Marcadores tumorales útiles en el cáncer de páncreas, Rev Cancer (Madrid), 26, 62 Hong, 2011, Molecular signatures of pancreatic cancer, Arch Pathol Lab Med, 135, 716, 10.5858/2010-0566-RA.1 Hiyama, 1997, Telomerase activity is detected in pancreatic cáncer but not in benign tumors, Cancer Res, 57, 326 Trede, 1990, Survival after pancreatoduodenectomy: 118 consecutive resections without an operative mortality, Ann Surg, 211, 447, 10.1097/00000658-199004000-00011 Neoptolemos, 2004, A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer, N Engl J Med, 350, 1200, 10.1056/NEJMoa032295 Oettle, 2007, Adjuvant chemotherapy with gemcitabine versus observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial, JAMA, 297, 267, 10.1001/jama.297.3.267 Klinkenbijl, 1999, Adjuvant radiotherapy and 5-Fluorouracil after curative resection of cancer of pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group, Ann Surg, 230, 776, 10.1097/00000658-199912000-00006 Kalser, 1985, Pancreatic cancer: Adjuvant combined radiation and chemotherapy following curative resection, Arch Surg, 120, 899, 10.1001/archsurg.1985.01390320023003 1987, Gastrointestinal Tumor Study Group: Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer, Cancer, 59, 2006, 10.1002/1097-0142(19870615)59:12<2006::AID-CNCR2820591206>3.0.CO;2-B Tempero, 2005, Pancreatic adenocarcinoma: clinical practice guidelines in oncology, J Nat Comp Cancer Netw, 3, 598, 10.6004/jnccn.2005.0035 Calvo, 2012, Tratamiento de la enfermedad locorregional. Contribución del componente radioterápico en cáncer de páncreas, Rev Cancer (Madrid), 26, 79 Chua, 2008, Pancreatic cáncer- is the wall crumbling?, Ann Oncol, 19, 1224, 10.1093/annonc/mdn063 Burris, 1997, Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial, J Clin Oncol, 15, 2403, 10.1200/JCO.1997.15.6.2403 Kindler, 2010, Gemcitabine plus bevacizumab compares with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the cancer and leukemia group B (CALGB 80303), J Clin Oncol, 28, 3617, 10.1200/JCO.2010.28.1386 Philip, 2010, Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group- Directed Intergroup Trial S0205, J Clin Oncol, 28, 3605, 10.1200/JCO.2009.25.7550 Moore, 2007, Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group, J Clin Oncol, 25, 1960, 10.1200/JCO.2006.07.9525 Conroy, 2011, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, N Engl J Med, 364, 1817, 10.1056/NEJMoa1011923 Boeck, 2008, Second line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer, J Clin Oncol, 26, 1178, 10.1200/JCO.2007.15.3304 Von Hoff, 2011, Gemcitabine plus nab-placlitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial, J Clin Oncol, 29, 4548, 10.1200/JCO.2011.36.5742